Merck's Keytruda continues its string of blockbuster results, but BMS' Opdivo still leads in sales
At the American Society of Clinical Oncology (ASCO) annual meeting over the weekend, Merck's Keytruda continued its winning streak.
Directing its reps to call on GPs with little to no opioid experience, Purdue introduced aggressive promotional tactics into the prescription opioid marketing playbook.
Biogen's recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
Meet "the connectors" as four of the best-regarded medical science liaisons and the leader of the MSL Society discuss what they do, how they do it, and why their work ...